Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. (Q44245989)

From Wikidata

Jump to navigation Jump to search

scientific article published on 9 September 2012

Language	Label	Description	Also known as
English	Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme.	scientific article published on 9 September 2012

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22862847%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22862847%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

phase III clinical trial

0 references

1 reference

ChEBI release 2020-05-28

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22862847%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

K Niswender

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22862847%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

X Pi-Sunyer

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22862847%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

K H Jensen

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22862847%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

A D Toft

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22862847%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

D Russell-Jones

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22862847%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

B Zinman

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22862847%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

publication date

9 September 2012

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22862847%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22862847%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22862847%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

42-54

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22862847%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22862847%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the Ameri

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01673.X

21 January 2018

Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01673.X

21 January 2018

Bariatric surgery: an IDF statement for obese Type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01673.X

21 January 2018

Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01673.X

21 January 2018

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01673.X

21 January 2018

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01673.X

21 January 2018

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01673.X

21 January 2018

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01673.X

21 January 2018

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01673.X

21 January 2018

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01673.X

21 January 2018

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01673.X

21 January 2018

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01673.X

21 January 2018

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01673.X

21 January 2018

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01673.X

21 January 2018

DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01673.X

21 January 2018

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01673.X

21 January 2018

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01673.X

21 January 2018

Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01673.X

21 January 2018

Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01673.X

21 January 2018

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01673.X

21 January 2018

Liraglutide: short-lived effect on gastric emptying -- long lasting effects on body weight.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01673.X

21 January 2018

Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01673.X

21 January 2018

The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01673.X

21 January 2018

Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01673.X

21 January 2018

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01673.X

21 January 2018

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01673.X

21 January 2018

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01673.X

21 January 2018

Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01673.X

21 January 2018

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01673.X

21 January 2018

Identifiers

10.1111/J.1463-1326.2012.01673.X

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22862847%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22862847%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44245989&oldid=2108885880"